tailieunhanh - Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study

Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a reallife setting. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN